4
Changes in Ownership
CytomX Therapeutics, Inc. Filed Acc 0001140361-17-045017
President and CEO sold 14,340 shares at $20.60 ($295,404)
- President and CEO acquired 14,340 shares (option exercise)
- President and CEO acquired 398 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| McCarthy Sean A. President and CEO | 2017-11-30 | Grant or award | +398 | $12.15 | $4,834 | 4,643 | D |
| McCarthy Sean A. President and CEO | 2017-12-01 | Option exercise | +4,100 | $0.95 | $3,875 | 8,743 | D |
| McCarthy Sean A. President and CEO | 2017-12-01 | Option exercise | +10,240 | $1.13 | $11,611 | 18,983 | D |
| McCarthy Sean A. President and CEO | 2017-12-01 | Sale | −14,340 | $20.60 | $295,404 | 4,643 | D |
| Derivatives | |||||||
| McCarthy Sean A. President and CEO | 2017-12-01 | Option exercise · Stock Option (right to buy) | −4,100 | 115,193 | D | ||
| McCarthy Sean A. President and CEO | 2017-12-01 | Option exercise · Stock Option (right to buy) | −10,240 | 356,721 | D | ||
| Open-market sales · 14,340 sh · avg $20.60 · $295,404 | |||||||
Loading xslF345X03/doc1.xml…